Overview
Novoic uses artificial intelligence to analyze spoken language to detect early signs of Alzheimer’s disease. It offers a software-based 10-minute speech test that runs on any smart device and is used by medical institutions, with 50+ centers currently adopting the technology. The company aims to extend access to underserved communities where detection is scarce. Revenue comes from selling the software to healthcare providers. Its AI models are validated through Novoic’s own clinical trials and trained on diverse datasets to improve accuracy and fairness.
Work here?Claim your company
Simplify's take
What believers are saying
- Novoic’s 2026 site says biomarker-confirmed trials improved robustness and equity.
- Browser-based testing on any smart device lowers deployment friction for hospitals.
- Speech biomarkers for amyloid prediction target faster triage than PET imaging workflows.
What critics are saying
- CB Insights still lists Novoic as Seed VC with $2.63M raised on 2026-11-08.
- No 2026 funding, hiring, or commercialization milestone suggests weak capital traction.
- A false-positive or biased model would damage clinical trust and stall ADNI-style adoption.
What makes Novoic unique
- Novoic’s 2026 product stack spans Storyteller, Dashboard, and Speech API.
- Its 2026 website says 50+ medical centers use its speech screening software.
- ADNI4 selected Novoic as the digital screener for 20,000 patients in 2022.
Help us improve and share your feedback! Did you find this helpful?